Record Detail Back
The Value of Genetic and Genomic Technologies
Slight variations in genetic composition can contribute greatly to the diversity which we see amongst individuals, from determining eye color and height to increasing the risk of developing breast cancer or heart disease. Numerous gene–disease associations are now known, and genetic/genomic testing is a relatively common laboratory approach for diagnosing presymp- tomatic genetic disorders, confirming an expressed genetic disease, screen- ing for markers of increased risk of disease, or determining if someone is an asymptomatic heterozygous carrier of a recessive disease. Genetic or genomic testing can be used to guide medical decision-making and treat- ment, ranging from personalized drug therapy to assessing an individual’s risk of developing common chronic diseases. However, these new technolo- gies have not been widely integrated into clinical practice and the question remains as to how these advances are valued in the health care setting. The Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health was established in 2007 to foster dialogue and partner- ships that will advance the field of genomics and improve the translation of basic genomic research to applications in health care, education, and health policy. Wylie Burke of the University of Washington, and chair of this roundtable, said that the discussions have brought to light some of the very diverse perspectives regarding which genomic applications will be potentially useful in practice as well as what represents compelling evidence to bring an application into the healthcare setting. A need was identified for a workshop to explore the concept of value in regards to genomics and genetics and how that concept affects the views of stakeholders and the ways they make decisions about using these tests and technologies.
Theresa Wizemann and Adam C. Berger - Personal Name
978-0-309-15771-1
NONE
Healthcare Management
English
2010
1-109
LOADING LIST...
LOADING LIST...